Date(s)

26 Oct 2021

Program Language

English

Meeting type

Virtual Meeting

Organizer

Educational Partner

Managing HIV Patients With Limited Treatment Options 2021

Related Enduring Materials

Enduring Materials

- 3:00

3:05 PM CEST

Epidemiology of Patients with Limited Treatment Options in Europe

Anna Maria Geretti, MD, PhD, FRCPath

University of Rome, Italy / King's College London, United Kingdom

Slideset

Video

· Provide epidemiological definition of patients with limited treatment options

· Present data on general epidemiology of this patient population in the world

· Focus on Europe and individual countries or regions

· Knowledge gaps and limitations of current data

3:25 PM CEST

Update on Clinical Trials of Drugs for Patients with Limited Treatment Options

Daniel Kuritzkes, MD

Brigham and Women's Hospital / Harvard Medical School, United States

Slideset

Video

· Review Data Recently Presented or Published on Drugs for Complex Patients

· Cover both updates and new analysis of older studies as well as new ones

· Briefly touch on clinical significance of these new data

3:45 PM CEST

Understanding and Managing Multi-Class Resistance

Roger Paredes, MD, PhD

Hospital Germans Trias & IrsiCaixa AIDS Research Institute, Spain

Video

· Current data on incidence and prevalence of acquired drug resistance in Europe

· Evaluating and interpreting drug resistance test data in clinical context

· Optimal use of resistance data to design an effective salvage regimen

4:05 PM CEST

Clinical Case #1: European Case Using New Agents in Patients with Multiple Drug Resistance

Georg Behrens, MD, PhD

Hannover Medical School, Germany

Slideset

Video

4:45 PM CEST

Pharmacological Considerations in Optimizing Care for Patients with Limited Treatment Options

Andrea Calcagno, MD, DTM&H

University of Turin, Italy

Slideset

Video

· Identifying significant drug-drug interactions with ARVs and co-medications

· Importance of considering herbal supplements

· Strategies to avoid and manage drug-drug interactions in complex patient

5:05 PM CEST

Immune Non-Responders - A Remaining Unmet Need

Marcus Altfeld, MD, PhD

Leibniz Institute for Experimental Virology (HPI), Germany

Slideset

Video

· Definition of immune non-responders

· Proposed mechanisms of poor immune reconstitution in patients

· New insights on potential therapeutic interventions

· Remaining knowledge gaps and ongoing research

5:25 PM CEST

Clinical Case #2: Patient with Immune Non-Response

Clíona Ní Cheallaigh, MB, BAO, BCh, MRCP, PhD

Trinity College Dublin, Ireland

Slideset

Video

6:00 PM CEST

Closure

Overview

Welcome

Despite improved antiretroviral regimens, virological failure and the emergence of drug resistance remains an ongoing challenge throughout Europe. This includes both patients who recently contracted the virus as well as veterans of older regimens. Although the resources, diagnostics, and soon drugs, required for the improved care of complex patients are now available in many parts of Europe, there remains a knowledge gap in how to best use them. Acquiring and interpreting resistance data correctly, incorporating co-morbidities and co-medications data, and then deciding on the optimal next regimen for patients with limited treatment options requires a high level of expertise. Managing these complex HIV patients requires greater knowledge and understanding in terms of adherence, resistance, aging, comorbidities, and polypharmacy.

This webinar has been designed for HIV physicians who would like to improve their knowledge of identifying and managing patients with limited treatment options, as well as new antiretroviral drugs for optimizing the treatment of these patients.

Program Director

Jonathan Schapiro, MD

National Hemophilia Center, Sheba Medical Center, Israel

General Information

COVID-19 Update

Responding to the changing COVID-19 situation, the Managing HIV Patients With Limited Treatment Options 2021 - European Edition will be held as a virtual conference on 26 October 2021, just prior to the EACS conference.

Who Should Attend?

This activity is intended for healthcare professionals actively involved in caring for people living with HIV, as some patients in their clinic will have limited treatment options and require management as heavily treatment-experienced patients.

Specifically:

- HIV physicians experienced in treating treatment-experienced patients with HIV who need to be informed and updated on new treatment options;

- HIV physicians inexperienced in treating complex HIV patients who need a more comprehensive education on identifying and managing treatment-experienced patients with an emphasis on new drugs;

- Clinical pharmacologists involved in the concomitant medication management and dose adjusting for co-morbidities of the treatment-experienced patient with HIV; and

- Other healthcare professionals (e.g. nurse practitioners) intimately involved in the medical care of treatment-experienced patients.

Learning Objectives

At the completion of the activity participants will have:

- Improved knowledge of the definition of treatment-experienced patients and the challenges of their care;

- Acquired tools and understanding on how best to Identify the treatment-experienced HIV patient in their clinical practice;

- Greater understanding of the new treatment options available for these patients, including recently presented clinical trials;

- Learned how best to integrate these new drugs into optimal combination regimens for treatment-experienced patients, considering their local country setting; and

- Improved their skills in managing drug-drug interactions and toxicities in these treatment-experienced patients.

Practical Information

Certificate of Attendance

A certificate of attendance will be sent to participants that successfully complete the meeting and post-meeting survey.

Language

The official language of the meeting is English.

Disclaimer

This meeting is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this meeting, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the meeting.

Liability and Insurance

By registering for the meeting participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.

Support

This program is supported by an independent educational grant from ViiV Healthcare.

ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Accreditation

The Symposium Managing HIV Patients With Limited Treatment Options 2021, Utrecht (Livestream), Netherlands, 26/10/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 2 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.